Literature DB >> 22301159

The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication.

Xiaoxia Wang1, Zhujun Ao, Liyu Chen, Gary Kobinger, Jinyu Peng, Xiaojian Yao.   

Abstract

The cytidine deaminase APOBEC3G (A3G) exerts a multifaceted antiviral effect against HIV-1 infection. First, A3G was shown to be able to terminate HIV infection by deaminating the cytosine residues to uracil in the minus strand of the viral DNA during reverse transcription. Also, a number of studies have indicated that A3G inhibits HIV-1 reverse transcription by a non-editing-mediated mechanism. However, the mechanism by which A3G directly disrupts HIV-1 reverse transcription is not fully understood. In the present study, by using a cell-based coimmunoprecipitation (Co-IP) assay, we detected the direct interaction between A3G and HIV-1 reverse transcriptase (RT) in produced viruses and in the cotransfected cells. The data also suggested that their interaction did not require viral genomic RNA bridging or other viral proteins. Additionally, a deletion analysis showed that the RT-binding region in A3G was located between amino acids 65 and 132. Overexpression of the RT-binding polypeptide A3G(65-132) was able to disrupt the interaction between wild-type A3G and RT, which consequently attenuated the anti-HIV effect of A3G on reverse transcription. Overall, this paper provides evidence for the physical and functional interaction between A3G and HIV-1 RT and demonstrates that this interaction plays an important role in the action of A3G against HIV-1 reverse transcription.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22301159      PMCID: PMC3302496          DOI: 10.1128/JVI.06594-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.

Authors:  Adam Jarmuz; Ann Chester; Jayne Bayliss; Jane Gisbourne; Ian Dunham; James Scott; Naveenan Navaratnam
Journal:  Genomics       Date:  2002-03       Impact factor: 5.736

2.  Hypermutation of HIV-1 DNA in the absence of the Vif protein.

Authors:  Denise Lecossier; Francine Bouchonnet; François Clavel; Allan J Hance
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

3.  DNA deamination mediates innate immunity to retroviral infection.

Authors:  Reuben S Harris; Kate N Bishop; Ann M Sheehy; Heather M Craig; Svend K Petersen-Mahrt; Ian N Watt; Michael S Neuberger; Michael H Malim
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

4.  The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes.

Authors:  J H Simon; M H Malim
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

5.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

Authors:  Ann M Sheehy; Nathan C Gaddis; Jonathan D Choi; Michael H Malim
Journal:  Nature       Date:  2002-07-14       Impact factor: 49.962

6.  Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.

Authors:  Roberto Mariani; Darlene Chen; Bärbel Schröfelbauer; Francisco Navarro; Renate König; Brooke Bollman; Carsten Münk; Henrietta Nymark-McMahon; Nathaniel R Landau
Journal:  Cell       Date:  2003-07-11       Impact factor: 41.582

7.  Assessment of the role of the central DNA flap in human immunodeficiency virus type 1 replication by using a single-cycle replication system.

Authors:  Zhujun Ao; Xiaojian Yao; Eric A Cohen
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.

Authors:  Hui Zhang; Bin Yang; Roger J Pomerantz; Chune Zhang; Shyamala C Arunachalam; Ling Gao
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

9.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Authors:  Bastien Mangeat; Priscilla Turelli; Gersende Caron; Marc Friedli; Luc Perrin; Didier Trono
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

10.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

View more
  54 in total

1.  Feline Immunodeficiency Virus Vif N-Terminal Residues Selectively Counteract Feline APOBEC3s.

Authors:  Qinyong Gu; Zeli Zhang; Lucía Cano Ortiz; Ana Cláudia Franco; Dieter Häussinger; Carsten Münk
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

2.  Virion-associated, host-derived DHX9/RNA helicase A enhances the processivity of HIV-1 reverse transcriptase on genomic RNA.

Authors:  Samantha Brady; Gatikrushna Singh; Cheryl Bolinger; Zhenwei Song; Ioana Boeras; Kexin Weng; Bria Trent; William Clay Brown; Kamalendra Singh; Kathleen Boris-Lawrie; Xiao Heng
Journal:  J Biol Chem       Date:  2019-06-07       Impact factor: 5.157

3.  Human immunodeficiency virus type 1 employs the cellular dynein light chain 1 protein for reverse transcription through interaction with its integrase protein.

Authors:  Kallesh Danappa Jayappa; Zhujun Ao; Xiaoxia Wang; Andrew J Mouland; Sudhanshu Shekhar; Xi Yang; Xiaojian Yao
Journal:  J Virol       Date:  2015-01-07       Impact factor: 5.103

Review 4.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

Review 5.  Role of the single deaminase domain APOBEC3A in virus restriction, retrotransposition, DNA damage and cancer.

Authors:  Yaqiong Wang; Kimberly Schmitt; Kejun Guo; Mario L Santiago; Edward B Stephens
Journal:  J Gen Virol       Date:  2015-10-20       Impact factor: 3.891

6.  Activation of TLR3/interferon signaling pathway by bluetongue virus results in HIV inhibition in macrophages.

Authors:  Ming Dai; Xu Wang; Jie-Liang Li; Yu Zhou; Ming Sang; Jin-Biao Liu; Jian-Guo Wu; Wen-Zhe Ho
Journal:  FASEB J       Date:  2015-08-21       Impact factor: 5.191

7.  Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.

Authors:  Zeli Zhang; Qinyong Gu; Ananda Ayyappan Jaguva Vasudevan; Manimehalai Jeyaraj; Stanislaw Schmidt; Jörg Zielonka; Mario Perković; Jens-Ove Heckel; Klaus Cichutek; Dieter Häussinger; Sander H J Smits; Carsten Münk
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

8.  Murine Leukemia Virus P50 Protein Counteracts APOBEC3 by Blocking Its Packaging.

Authors:  Wenming Zhao; Charbel Akkawi; Marylène Mougel; Susan R Ross
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

9.  Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.

Authors:  Kieran Gillick; Darja Pollpeter; Prabhjeet Phalora; Eun-Young Kim; Steven M Wolinsky; Michael H Malim
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

10.  Murine leukemia virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to the reverse transcription complex.

Authors:  Spyridon Stavrou; Takayuki Nitta; Swathi Kotla; Dat Ha; Kunio Nagashima; Alan R Rein; Hung Fan; Susan R Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.